6533b821fe1ef96bd127b840
RESEARCH PRODUCT
Is elimination of HCV in 2030 realistic in Central Europe.
Marieta SimonovaIeva TolmaneIvica GrgurevićDorota Zarębska-michalukMichael MakaraLimas KupčinskasPeter JarcuskaBéla HunyadySona FrankovaRobert FlisiakJan SperlAdriana Vincesubject
medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Hepatitis C virusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.disease_causeAntiviral Agents03 medical and health sciences0302 clinical medicineEpidemiologymedicinePrevalenceHumansHepatologybusiness.industrySARS-CoV-2virus diseasesCOVID-19Hepatitis Cmedicine.diseaseVirologyHepatitis Cdigestive system diseasesHcv eliminationEuropeRegimen030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessdescription
According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-06-01 | Liver international : official journal of the International Association for the Study of the LiverREFERENCES |